Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

NCT05677100 · View on ClinicalTrials.gov ↗

Study Summary

Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.

Interventions

  • DEVICE Aortix System

Study Locations (20)

Florida

  • Ascension Sacred Heart — Pensacola
  • Tallahassee Research Institute — Tallahassee
  • University of South Florida — Tampa
  • BayCare Medical/St. Joseph's Hospital — Tampa
  • AdventHealth Tampa — Tampa
  • Cleveland Clinic Florida — Weston

California

  • John Muir Health — Concord
  • Zuckerberg San Francisco General — San Francisco
  • San Francisco Veterans Administration — San Francisco
  • University of California San Francisco — San Francisco

Arizona

  • Banner--University Medical Center Phoenix — Phoenix
  • Mayo Clinic - Arizona — Phoenix
  • HonorHealth Medical Center — Scottsdale

Georgia

  • Emory University Hospital — Atlanta
  • Piedmont Healthcare Inc. — Augusta
  • Wellstar Research Institue — Marietta

Illinois

  • University of Chicago — Chicago
  • Advocate IMMC — Chicago
  • Advocate Aurora - Good Samaritan — Downers Grove

Kansas

  • Ascension via Christi Kansas — Wichita

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2023-08-23
Est. Completion 2027-08
Phase NA

Sponsor

Procyrion

29 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05677100

The ClinicalTrials.gov registry entry for NCT05677100 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Procyrion, which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 8 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which Aortix System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05677100 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05677100 about?

NCT05677100 is a clinical study titled "Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure". Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec...

What is the current status of trial NCT05677100?

This trial is currently recruiting. It is a NA study. The enrollment target is 320 participants. The study started on 2023-08-23. Estimated completion is 2027-08.

What conditions does trial NCT05677100 study?

This clinical trial studies the following conditions: Heart Failure, Heart Failure, Congestive, Heart Failure, Diastolic, Heart Failure, Systolic, ADHF. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05677100?

The interventions under investigation include: Aortix System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05677100?

This trial is sponsored by Procyrion, which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05677100 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial